Skip to main content
. 2018 Apr 23;10(4):127. doi: 10.3390/cancers10040127

Figure 4.

Figure 4

A combination of tirabrutinib and idelalisib or lenalidomide can overcome BTK-inhibitor resistance. TMD8R cells were treated with indicated doses of tirabrutinib combined with 100 nM of idelalisib or 1000 nM of lenalidomide for 72 h. Apoptosis was determined by AnnexinV-FITC staining by flow cytometry. The combination index was calculated using Calcusyn (Biosoft, Ferguson, MO, USA).